About OSI Pharmaceuticals

OSI Pharmaceuticals, acquired by Astellas Pharma Inc. in 2010, is a leading biotechnology company focused on the discovery and development of high-quality, next-generation oncology products to both extend and improve the lives of cancer patients worldwide. The acquisition of OSI is expected to augment Astellas' strong existing franchises in urology and transplantation, expanding the product portfolio and pipeline of the combined company. OSI serves as Astellas’ small molecule research arm and focuses on developing mechanism-based approaches to drug discovery directed at the processes underlying the role of the Epithelial Mesenchymal Transition in the development of cancer. OSI has a balanced pipeline of oncology drug candidates that includes both mechanism-based, gene-targeted therapies focused in the areas of signal transduction and apoptosis and next-generation cytotoxic chemotherapy agents. OSI discovered and developed Tarceva® (erlotinib), a leading cancer medication, and has several prospective new oncology candidates in the R&D pipeline.

For additional information about the company, please visit www.astellas.us.

Company Contact Information
Maribeth Landwehr, Director
Corporate Communications